

SYMPOSIUM AGENDA

- 6:00 – 6:15 AM **Registration & Meal Service**
- 6:15 – 6:20 AM **Welcome and Introduction**
Andrew J. Ahmann, MD
- 6:20 – 6:55 AM **Symposium**
- Overview of benefits and challenges of insulin initiation
 - Newly approved insulin glargine U-300 (concentrated basal insulin)
 - Emerging PEGylated insulin lispro (LY2605541)
 - Emerging insulin degludec (ultra-long-acting insulin)
 - Head-to-head summary
- Andrew J. Ahmann, MD*
- 6:55 – 7:05 AM **Question Review and Clinical Case Presentation**
- 7:05 – 7:15 AM **Audience Q&A and Closing Remarks**

FACULTY

Andrew J. Ahmann, MD
Professor of Medicine
Director, Harold Schnitzer Diabetes Health Center
Oregon Health & Science University
Portland, Oregon

ACCREDITATION STATEMENT

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Endocrine Society has achieved Accreditation with Commendation.

The Endocrine Society designates this live activity for a maximum of 1.0 *AMA PRA Category 1 Credit™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

LEARNING OBJECTIVES

Upon completion of this educational activity, learners will be better able to:

- Evaluate the benefits of initiating insulin therapy and summarize common barriers to basal insulin therapy
- Summarize benefits and limitations of new and emerging basal insulins
- Select among basal insulin and non-insulin therapies to improve glycemic outcomes and minimize adverse effects taking individual patient contexts into consideration

TARGET AUDIENCE

This continuing medical education activity should be of substantial interest to endocrinologists, endocrine fellows, and healthcare professionals who treat patients with diabetes.

STATEMENT OF INDEPENDENCE

As a provider of continuing medical education (CME) accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society's Special Programs Committee (SPC). The commercial supporter(s) of this activity have no influence over the planning of this CME activity.

DISCLOSURE POLICY

The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The faculty reported the following relevant financial relationship(s) during the content development process for this activity:

Andrew J. Ahmann, MD: *Consultant, Lilly, Sanofi; Research Grant Support, Novo Nordisk*

The following SPC member who reviewed content for this activity reported relevant financial relationships:

Guillermo E Umpierrez, MD, CDE: *Advisory Board and Consultant, Abbott, Boehringer Ingelheim, Merck, Novo Nordisk, Regeneron, Sanofi; Research Grant Support, Boehringer Ingelheim, Merck & Co., Novo Nordisk, Regeneron*

The following SPC Committee members reported relevant financial relationships:

Sarah Berga, MD: *Advisory Board Member, Agile Therapeutics, Noven Pharmaceuticals, Inc., Watson Pharmaceuticals, Teva Pharmaceuticals Industries, Shionogi, Inc.; Consultant, AHC Media, LLC, Shionogi, Inc.*

Paresh Dandona, MD, PhD, FRCP: *Consultant and Speaker, AstraZeneca, Bristol Myers Squibb, Janssen, Merck, Novo Nordisk*

Irl B Hirsch, MD: *Consultant, Abbott Laboratories, Becton Dickinson, Roche Diagnostics; Grant Support, Halozyme, Sanofi*

E. Michael Lewiecki, MD: *Consultant, Amgen, Eli Lilly, Merck, Radius Health, AgNovos Healthcare, Theranova; Research Grant Support, Amgen, Eli Lilly, Merck*

Lisa Nachtigall, MD: *Consultant, Genentech; Consultant and Principal Investigator, Ipsen*

Amy Rothberg, MD: *Consultant, Novo Nordisk; Speaker, Takeda Pharmaceuticals*

The following SPC members reported no relevant financial relationships: **John Carmichael, MD; Natalie Cusano, MD; Larry Fox, MD; Michael S Irwig, MD; Connie B Newman, MD**

Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.

DISCLAIMER

The information presented in this activity represents the opinion of the faculty and is not necessarily the official position of the Endocrine Society.

Use of professional judgment:

The educational content in this activity relates to basic principles of diagnosis and therapy and does not substitute for individual patient assessment based on the health care provider's examination of the patient and consideration of laboratory data and other factors unique to the patient. Standards in medicine change as new data become available.

Drugs and dosages:

When prescribing medications, the physician is advised to check the product information sheet accompanying each drug to verify conditions of use and to identify any changes in drug dosage schedule or contraindications.

POLICY ON UNLABELED/OFF-LABEL USE

The Endocrine Society has determined that disclosure of unlabeled/off-label or investigational use of commercial product(s) is informative for audiences and therefore requires this information to be disclosed to the learners at the beginning of the presentation. Uses of specific therapeutic agents, devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the Food and Drug Administration (FDA). The Endocrine Society requires that any discussions of such "off-label" use be based on scientific research that conforms to generally accepted standards of

experimental design, data collection, and data analysis. Before recommending or prescribing any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse events.

PRIVACY AND CONFIDENTIALITY STATEMENT

The Endocrine Society will record learner's personal information as provided on CME evaluations to allow for issuance and tracking of CME certificates. The Endocrine Society may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its CME program. No individual performance data or any other personal information collected from evaluations will be shared with third parties.

ACKNOWLEDGEMENT OF COMMERCIAL SUPPORT

This activity is supported by an educational grant from sanofi-aventis U.S. Inc.

AMA PRA CATEGORY 1 CREDIT™ (CME) INFORMATION

The Endocrine Society designates this live activity for a maximum of 1.0 *AMA PRA Category 1 Credit™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

To receive a maximum of 1.0 *AMA PRA Category 1 Credits™* participants must complete the activity evaluation online at education.endocrine.org/DM2CEU15 by October 30, 2015. After completing the evaluation, you will be able to save or print a CME certificate.

For questions about content or obtaining CME credit, please contact the Endocrine Society at education.endocrine.org/contact.

FACULTY BIOGRAPHY



Andrew Ahmann, MD

Dr. Andrew Ahmann is Professor of Medicine at Oregon Health and Science University (OHSU) in Portland, Oregon. He is the Director of the Harold Schnitzer Diabetes Health Center, a combined pediatric and adult comprehensive diabetes center for patient care and clinical research. He is also Director of Diabetes Services at OHSU. As an endocrinologist/ diabetologist, Dr. Ahmann has remained active in patient care, medical education, advocacy, professional organizations and clinical research.